Business Wire

OK-OSU

16.12.2021 14:02:09 CET | Business Wire | Press release

Share
Historic Donation Establishes Hamm Institute for American Energy at Oklahoma State University

The Harold Hamm Foundation and Continental Resources announced today a combined $50 million gift creating the Hamm Institute for American Energy at Oklahoma State University.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215006096/en/

The Hamm Institute’s mission is to educate the next generation of energy leaders — in Oklahoma, the United States and from around the world — cementing Oklahoma’s legacy as a global energy leader.

“The generous gifts from Harold Hamm and Continental Resources to establish the Hamm Institute for American Energy will have a transformative impact on OSU and the energy sector worldwide. With a state-of-the art lab featuring wells drilled below the building, an auditorium, and classrooms, this building is fit for purpose,” OSU President Kayse Shrum said. “Mr. Hamm’s and Continental’s generosity will bring together the brightest minds and future energy sector leaders from around the world, all with a goal of solving one of society’s most pressing concerns. Together, we will change the trajectory of energy security in the United States.”

The initial funding for the institute and project will be a gift of $50 million dollars — $25 million from the Harold Hamm Foundation and $25 million from Continental Resources. The Hamm Institute will be located in what was formerly known as OSU Discovery, 300 NE 9th St. in the Oklahoma City Innovation District, and will become the primary and permanent occupant of the building.

The Hamm Institute will become the center of all things American energy. It will host symposiums, authors, speakers, energy summits and global energy leadership conversations. The building will eventually house the Oklahoma Hall of Energy Legends Interactive Museum, a public exhibit highlighting the history and storied legacy of Oklahoma’s great energy leaders.

Hamm, a native Oklahoman and founder and chairman of Continental Resources, began his career in oil and gas over five decades ago, starting out with a single oil service truck and a dream. His incredible journey, entrepreneurial spirit and will to change the world for the better have inspired countless others, and his latest philanthropic push aims to elevate the state to both new and familiar heights.

Hamm is recognized as a national leader and staunch advocate of America’s domestic oil and natural gas industry. He has spent over five and a half decades in the industry, from starting his own oil services business to founding one of America’s most dynamic and innovative exploration and production companies, Continental Resources. His efforts have contributed to the well-being of every American and are helping secure the nation’s energy and economic security. The Hamm Institute will ensure America leads the world when it comes to advancing innovation and technology while responsibly producing the energy we need for decades to come.

“It’s time, once again, for Oklahoma to become a global energy leader. It’s my hope the world will look to us for the best ideas when it comes to energy stewardship, research, and education. This gift is about investing in our shared future — the future of our country and the state and people I love,” Hamm said. “I see the Institute as a game changer — a place where the best and the brightest will come together to responsibly solve the world’s energy challenges. A third of the world lives in energy poverty. We need to fix that. And we need to make sure Americans will always have an abundance of reliable, affordable energy for generations to come.”

“Oklahoma is an energy state and Harold is our energy icon. This collaboration between one of our great universities and one of our most innovative and successful energy companies and entrepreneurs will raise the bar for American energy innovation,” said Oklahoma Gov. Kevin Stitt.

In acknowledgement of Continental’s contributions, the building’s concourse and auditorium will be named as the Continental Resources Concourse and Continental Resources Auditorium. The program fund supporting the institute also will be named in recognition of Continental.

“The Hamm Institute belongs here in Oklahoma. It is part of the Continental mission – to find, nurture and inspire the next generation of energy leaders. We envision the Hamm Institute for American Energy to be the epicenter of learning, research and energy innovation for decades to come,” said Bill Berry, Continental Resources CEO.

P​​HOTOS/VIDEO: A multimedia package including b-roll, soundbites and photos is available for media use here: okla.st/hamm .

REBROADCAST: View the rebroadcast of this announcement at insideosu.com .

Oklahoma State University is a modern land-grant university that prepares students for success. OSU has more than 34,000 students across its five-campus system and more than 24,000 on its combined Stillwater and Tulsa campuses, with students from all 50 states and around 100 nations. Established in 1890, OSU has graduated more than 275,000 students to serve the state of Oklahoma, the nation and the world.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye